Mustafa Khasraw, Mbchb, Md, Frcp, Fracp

This early-stage study tests a new drug called BRiTE in 18 adults with a specific type of glioblastoma (EGFRvIII-positive). BRiTE is designed to help the body's immune T cells attack the tumor. It is given as a continuous 4-day IV infusion every 28 days. The main goal is to check…